The committee recommended six of seven peptides for the list pharmacies may compound from, overruling FDA staff. The votes are not binding, none of the six has been listed yet, and the science has not changed.
On July 23 and 24, 2026, the FDA’s Pharmacy Compounding Advisory Committee reviewed seven peptides for the 503A bulk drug substances list, the list licensed pharmacies may compound from. It recommended six: BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon. It did not recommend emideltide, better known as DSIP.
The votes were narrow and went against the agency’s own reviewers. FDA staff had recommended against listing all seven, citing short, underpowered studies. On BPC-157, eight members voted yes, six voted no and one abstained.
The committee advises; it does not decide. None of the six peptides has been added to the 503A list, and none is an FDA-approved drug. Listing would require the FDA to accept the recommendations and then complete notice-and-comment rulemaking: a proposed rule, a public comment period and a final rule. Until then, pharmacies may not compound these substances from bulk.
A favorable vote is a statement about legal supply. It adds no new evidence about whether these peptides work in people. For most of them the human data remain thin, and the strongest results still come from animals.
Whether the FDA accepts the recommendations, how quickly it publishes a proposed rule, and whether it attaches conditions to specific uses. We have updated our reclassification explainer and our pages on Epitalon, MOTS-C and DSIP.